Gonadotropin-releasing hormone (GnRH) and its natural
analogues: A review Falk Schneider a, * , Wolfgang Tomek a , Carsten Grundker b a Department of Reproductive Biology, Research Institute for the Biology of Farm Animals, Wilhelm-Stahl-Allee 2, D-18196 Dummerstorf, Germany b Department of Gynecology and Obstetrics, Georg-August-University, Gottingen, Germany Received 28 July 2005; received in revised form 20 January 2006; accepted 17 March 2006 Abstract The pivotal role of gonadotropin-releasing hormone (GnRH) during the hormonal regulation of reproductive processes is indisputable. Likewise, many factors are known to affect reproductive function by inuencing either GnRH release from hypothalamus or pituitary gland responsiveness to GnRH. In veterinary medicine, GnRH and its agonists (GnRHa) are widely used to overcome reduced fertility by ovarian dysfunction, to induce ovulation, and to improve conception rate. GnRHa are, moreover, integrative part of other pro-fertility treatments, e.g. for synchronization of the estrous cycle or stimulation for embryo transfer. Additionally, continuous GnRH which shows desensitizing effects of the pituitary-ovarian axis has been recommended for implementation in anti-fertility treatments like inhibition of ovulation or reversible blockade of the estrous cycle. Just as much, another group of GnRH analogues, antagonists, are now in principle disposable for use. For a few decades, GnRH was thought to be a unique structure with a primary role in regulation gonadotropins. However, it became apparent that other homologous ligands of the GnRH receptor (GnRHR) exist. In the meantime, more than 20 natural variants of the mammalian GnRH have been identied in different species which may compete for binding and/or have their own receptors. These GnRH forms (GnRHs) have apparently common and divergent functions. More studies on GnRHs should contribute to a better understanding of reproductive processes in mammals and interactions between reproduction and other physiological functions. Increased information on GnRHs might raise expectations in the application of these peptides in veterinary practice. It is the aimof this reviewto discuss latest results fromevolutionarily based studies as well as rst experimental tests and to answer the question howrealistic might be the efforts to develop effective and animal friendly practical applications for endogenous GnRHs and synthetic analogues. # 2006 Elsevier Inc. All rights reserved. Keywords: Reproduction; Farm animals; GnRH; Hypothalamus; Gonadotropin Contents 1. Introduction to gonadotropin-releasing hormone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 692 2. Biosynthesis and storage of GnRH-I and its natural analogues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 692 3. Release mechanisms of GnRH-I . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 694 4. Reception of GnRH-I and its variants. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 696 www.journals.elsevierhealth.com/periodicals/the Theriogenology 66 (2006) 691709 * Corresponding author. Tel.: +49 38208 68757; fax: +49 38208 68752. E-mail address: falk.schneider@fbn-dummerstorf.de (F. Schneider). 0093-691X/$ see front matter # 2006 Elsevier Inc. All rights reserved. doi:10.1016/j.theriogenology.2006.03.025 5. Hypophyseal and extrahypophyseal effects of natural GnRHs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 698 6. Use of GnRH-I and its natural forms in farm animals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 700 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 703 1. Introduction to gonadotropin-releasing hormone GnRHbelongs to a group of neuropeptides originally discovered and successfully isolated as factors of hypothalamic origin that control secretions of the anterior pituitary gland. GnRH inuences reproductive processes, mainly by regulating pituitary gonadotropin synthesis and release, which in turn modulate ster- oidogenesis and gametogenesis. This pivotal role may explain why the interest in GnRH is still going on since its primary structure was revealed in pigs [1] and sheep [2]. GnRH is expressed, apart from hypothalamus, in numerous peripheral tissues including gonads and placenta [310]. Hypothalamic and extrahypothalamic GnRH are known as integrated part of multiple paracrine/autocrine axes. Hypothalamic GnRH, how- ever, is in the focus of attention of the present review. There are currently 23 identied naturally occurring GnRH analogues (GnRHs) across the vertebrate species [1113]. These variants show multiple substitutions in their amino acid (AA) sequence when compared with the mammalian GnRH (mGnRH), and they were widely distributed in tissues suggesting that they have acquired signicant functions throughthe phylogeny. GnRHs have been explored during last years in various classes of vertebrates, mainly in shes and mammals, but also in protochordates, that are phylogenetically distant from mammalian vertebrates. The species-related designation of single GnRH isoforms may be difcult to survey and confusing under circumstances. In this review mGnRH will always be designated, according to [14], GnRH-I, chicken GnRH-II (cGnRH-II) GnRH-II, and salmon GnRH (sGnRH) GnRH-III. Other GnRHs will be preferably discussed by citing the traditional names which have been introduced in the literature. It was assumed that dogsh GnRH, GnRH-II, and GnRH-III are ancient forms which could be likely found in inverte- brates [15]. At this stage, the exploration of the primary structure of GnRHs has been completed only in tunicates and octopus. More information seems to be necessary to complete the phylogenetic tree of GnRH and to characterize the ontogenic development of single GnRHs in different species [16]. GnRH-I and its variants are thought to have neuroendocrine, as well as neurotransmitter and neuro- modulatory functions [13,17]. The neuroendocrine axis plays the central role in the control of reproduction, and GnRH-I is well known to integrate internal and external signals of the nervous system to reproductive system [15]. In invertebrates, a similar role of GnRHs may have evolved resulting in systems that assure the maintenance of species under changing environments. However, GnRH-I also acts as a neuromodulator probably by down-regulation of its neighboring genes for particular protein-tyrosin phosphatases [18]. This GnRH-I function could be an important link of the common molecular mechanism underlying the diverse functions of GnRHs. It is evident that at least two of these natural GnRHs are present in more than 80 vertebrate species [12 14,1921]. A better understanding is, however, still needed to evaluate the specic contribution of GnRHs to the control of mammalian reproduction by GnRH-I in mammals. The practical usefulness of GnRH-I and its synthetic analogues (agonists and antagonists) has achieved a high level. It is the purpose of the present review to discuss in this context the prospects for GnRH-II and other GnRHs although the exact functions of these peptides are yet to be dened [22]. 2. Biosynthesis and storage of GnRH-I and its natural analogues Like many other proteins and peptides, GnRH-I and its analogues are enzymatically processed from larger precursors (Fig. 1). The complementary DNA consists of the decapeptide, extended at the amino (N) terminus by a signal peptide, and at the carboxy (C) terminus by a Gly-Lys-Arg sequence followed by the GnRH-asso- ciated peptide (GAP). In the proGnRH-I, the GAP sequence is 56 AA long but it shows, like the signal peptide, considerable variations between several mammals [3] like that of pro-GnRHs of other species [23,24]. GAP which is F. Schneider et al. / Theriogenology 66 (2006) 691709 692 Fig. 1. Schematic representation of the prepro-GnRH precursor pro- teins. The 5 0 -untranslated region (5 0 utr) is followed by the signal peptide (SP), the GnRH, processing signal (*), the GnRH-associated peptide (GAP), and the 3 0 -untranslated region (3 0 utr). Adapted to Sherwood et al. [3]. consequently co-secreted with GnRH [10,25] may be involved in the correct processing and packing of the decapeptide [3]. The processing of GnRH-I occurs within about 1000 GnRH neurons that do not reside in dened cytoarchitectonic bound-areas among different species [26]. GnRH neurons are distributed in a loose array along the ventral medial forebrain from the posterior olfactory bulbs to the arcuate nucleus. GnRH neurons are found in the vicinity of the olfactory placode during prenatal development, and then the GnRH-producing cells migrate through the nasal system into the forebrain [27]. Therefore, differences in GnRH-producing areas within the brain appear to result from greater or lesser penetration along the olfactory-forebrain-hypothalamus continuum to the median eminence. The unusual developmental course of GnRH neurons may represent a vestige of the pheromonal control of reproductive function and, thus, explain the release and transportation of GnRH into the hypothalamus-pituitary portal vasculature and the clinical link between reproductive failure and olfactory dysfunction, respectively [28]. Apart from GnRH-I and, very often, GnRH-II [17,2931] the presence of a third form, lamprey GnRH-III (lGnRH-III), has been determined in neurons of the preoptic-hypothalamic region of the rat, both alone and together with GnRH-I [32]. Others were, however, not able to isolate lGnRH-III in humans [8,30] or in hamster and rat brains [29]. The primary AA structure of most GnRHpeptides is common: a length of 10 AA and conserved AA in positions 1 to 4, 9, and 10 (Table 1). The compositions of the peptide chains of natural GnRHs show a range of substituted AA from one (e.g. cGnRH-I) to ve (lGnRH-I) compared with GnRH-I. The AA sequence of GnRH-II shows, for example, differences in positions 5 (His for Tyr), 7 (Trp for Leu), and 8 (Tyr for Arg), compared with that of GnRH-I. There are, however, some striking exceptions of common composition, e.g. the sequences of guinea pig (gp)GnRH, lGnRH-I, and octopus (o)GnRH [15,17] (Table 1). The listing of GnRHs demonstrates that the main part of them was found in evolutionarily old life forms and fewer variants occur in mammals, respectively [33]. F. Schneider et al. / Theriogenology 66 (2006) 691709 693 Table 1 Amino acid composition of GnRH-I and its 23 natural analogues in vertebrates and invertebrates Amino acid 1 2 3 4 5 6 7 8 9 10 Vertebrate Mammal (GnRH-I) pGlu His Trp Ser Tyr Gly Leu Arg Pro Gly.NH2 Guinea Pig pGlu Tyr Trp Ser Tyr Gly Val Arg Pro Gly.NH2 Chicken-I pGlu His Trp Ser Tyr Gly Leu Gln Pro Gly.NH2 Rana pGlu His Trp Ser Tyr Gly Leu Trp Pro Gly.NH2 Seabream pGlu His Trp Ser Tyr Gly Leu Ser Pro Gly.NH2 Salmon (GnRH-II) pGlu His Trp Ser Tyr Gly Trp Leu Pro Gly.NH2 Whitesh pGlu His Trp Ser Tyr Gly Met Asn Pro Gly.NH2 Medaka pGlu His Trp Ser Phe Gly Leu Ser Pro Gly.NH2 Catsh pGlu His Trp Ser His Gly Leu Asn Pro Gly.NH2 Herring pGlu His Trp Ser His Gly Leu Ser Pro Gly.NH2 Chicken-II (GnRH-II) pGlu His Trp Ser His Gly Trp Tyr Pro Gly.NH2 Dogsh pGlu His Trp Ser His Gly Trp Leu Pro Gly.NH2 Lamprey-III pGlu His Trp Ser His Asp Trp Lys Pro Gly.NH2 Lamprey-I pGlu His Tyr Ser Leu Glu Trp Lys Pro Gly.NH2 Invertebrate Octopus pGlu Asn Tyr His Phe Ser Asn Gly Trp His Pro Gly.NH2 Tunicate-I pGlu His Trp Ser Asp Tyr Phe Lys Pro Gly.NH2 Tunicate-II pGlu His Trp Ser Leu Cys His Ala Pro Gly.NH2 Tunicate-III pGlu His Trp Ser Tyr Glu Phe Met Pro Gly.NH2 Tunicate-IV pGlu His Trp Ser Asn Gln Leu Thr Pro Gly.NH2 Tunicate-V pGlu His Trp Ser Tyr Glu Tyr Met Pro Gly.NH2 Tunicate-VI pGlu His Trp Ser Lys Gly Tyr Ser Pro Gly.NH2 Tunicate-VII pGlu His Trp Ser Tyr Ala Leu Ser Pro Gly.NH2 Tunicate-VIII pGlu His Trp Ser Leu Ala Leu Ser Pro Gly.NH2 Tunicate-IX pGlu His Trp Ser Asn Lys Leu Ala Pro Gly.NH2 Bold letters: primary structure of GnRH-I and identical amino acids in variants. Adapted to Gorbman and Sower [15] and Millar et al. [17]. The most ancient GnRH form is thought to be oGnRH [34]. Another form of GnRH, 9-hydroxyproline GnRH- I (Hyp 9 -GnRH), has been reported to be present in various mammals like rats and dogs. The peptide has a nearly identical structure to GnRH-I but the small difference in the 9th AA makes it less sensitive to prolyl endopeptidase [3537]. The answer to the question whether various GnRH forms [38] and their genes [21,3943], respectively, are present in a distinct species may have some importance for the under- standing of the evolution and be helpful to draw up specic functions of GnRHs in mammals. The phylogenetic tree which was recently established [15] contains the AA structures of the natural GnRHs (Fig. 2). The GnRH-II structure ([His 5 ,Trp 7 ,Tyr 8 ]-GnRH; Table 1) has been conserved over 500 million years [12,21]. GnRH-II is one of the GnRHs that appears to be predominantly expressed in other tissues such as the reproductive system [22]. In the brain of mammals, the vast majority of GnRH-II cell bodies are localized to the midbrain, with a few present in hypothalamic and extrahypothalamic regions [44] and a minority of ber projections fromneurons containing GnRH-II project to the median eminence or regions that regulate gonado- tropin release [45]. In the human, however, GnRH-II is expressed at signicantly higher levels outside the brain, e.g. in the kidney, bone marrow, and prostate [40]. Other species-specic prerequisites of the biosynthesis of GnRHs were reported for lGnRH-III [46] and GnRH- III [47] in several mammals. 3. Release mechanisms of GnRH-I The release of hypothalamic GnRH-I is not continuous but pulsatile. The episodic release of GnRH during the female reproductive cycle is seen as a prerequisite for fertility. Multiple rhythms interact to generate GnRH-I pulses, thus high-frequency burst rhythms decrease during peaks in the low-frequency rhythm with approximately 20 min duration. The pulsatile release pattern is the predominant one in most physiological circumstances. The sole exception to pulsatility is at the time of the preovulatory LH. Several theses were postulated to understand the mechanisms underlying episodic GnRH-I release. One of the theses is that interactions among GnRH neurons should be crucial for synchronizing and modulating the low-frequency rhythm which is asso- ciated with hormone release [48]. Numerous loops, ultra-short, short and long in length, form a link between the hormone-secreting tissues. Paracrine interactions among GnRH neurons are known, for example, as the rst proposed ultra-short loop [49]. The real frequency of GnRH pulses in an individual is species-specic and depends on its gonadal hormone status and numerous other factors [50,51]. The role of the ovarian steroids estradiol (E 2 ) and progesterone (P 4 ) in the control pulsatile GnRH secretion and generation of the preovulatory GnRH surge to induce the release of the LH surge seems to be well investigated [23,52]. Both steroids interfere with gonadotropin regulation by modifying the secretion of F. Schneider et al. / Theriogenology 66 (2006) 691709 694 Fig. 2. Phylogenetic analysis of 24 GnRH primary amino acid structures (bold letters: GnRHs with demonstrated or supposed importance to mammalian reproduction). Adapted to Gorbman and Sower [15]. GnRH or exhibit a direct effect on gonadotropin- secreting cells in the anterior pituitary gland. There is some evidence to suggest that the negative feedback actions of E 2 are manifest in the suppression of GnRH pulse amplitude and P 4 may primarily exert its effects on GnRHpulse frequency. In the mid-luteal phase of the estrous cycle, for example, the negative feedback of P 4 suppressed GnRH release as well as decreased the expression of the GnRH mRNA in heifers [53]. In sheep, the negative feedback of E 2 on the episodic GnRH secretion was found to be highly effective during anestrus [54]. The understanding of the effects of gonadal steroids on synthesis of GnRH-I is less clear than that on secretion [23]. Apart from direct effects other effects are transmitted through steroid-responsive neuronal systems in various parts of the brain. They can override direct effects under special situations, e.g. undernutrition and stress. High levels of estrogens produced during the preovulatory period exert a positive feedback action, probably by culminating in the release of increased GnRHamounts and gonadotropin surges. Previously, it was assumed that E 2 stimulates the expression of the gene encoding the GnRH receptor. The increase precedes the preovulatory rise in circulating concen- trations of E 2 . The enhanced pituitary sensitivity to GnRH may occur as a result of a decrease in concentrations of P 4 rather than in an increase in E 2 concentrations [55]. Moreover, there have been reported effects of various hormones of non-reproductive organs and tissues, e.g. cortisol from adrenals or leptin from fat cells, which may act on the hypothalamus to inuence pulsatile GnRH release and/or on the pituitary gland to inhibit gonadotropin responsiveness to GnRH [5662]. The secretion of GnRH during the reproductive cycle is, furthermore, the result of qualitative and quantitative modications in neurotransmitter systems, e.g. cate- cholaminergic, opioidergic and GABAergic systems, which show great differences in their impact [8,23,63 70]. It was summarized [71] that many compounds can potentially modify the GnRH-I-induced secretion of gonadotropins by different ways: Peptides, e.g. oxytocin, are transported from the hypothalamus and directly acts on the gonadotrope. There is an interaction of the peptides, e.g. neuropep- tide Y, from the hypothalamus with GnRH-I. Peptide elicits release of another substance that acts on the gonadotrope and so produces a paracrine mechanism of action, e.g. PACAP stimulates IL-6 release from folliculo-stellate cells. Peptide is released froma cell within the pituitary, e.g. galanin from lactotropes. An autocrine process utilizing peptide synthesized within the gonadotrope, e.g. substance P. The gonadotropins LH and FSH are dimeric glycoprotein hormones, showing a common a-subunit while possessing distinct b-subunits, the latter con- ferring biological actions [72]. The subunits are encoded by different genes, and the expression may be regulated in either a coordinate or differential fashion [73]. Gonadal steroid and peptide hormones can exert selective actions on one or more of the subunit gene products [52,74]. It is a striking feature that GnRH induces potentiation of its own action on the LH response by the phenomenon self-priming which means a biphasic LH response. Recently, it was argued that ovarian factor(s) like the putative gonadotropin- surge inhibiting factor/attenuating factor exerts inhibi- tory effects on the amount of circulating gonadotropins at the pituitary but rather at the hypothalamus level itself. The steep increase in LH responsiveness occurs only after the elimination of this inhibitory action by GnRH [75]. Gonadal peptides may also be responsible for the fact that the GnRH surge consistently continued well beyond the surge of LH [76]. The importance of the episodic GnRH signal to the pituitary gonadotropes was demonstrated over two decades ago by Knobil and his colleagues. These studies revealed that in the presence of a continuous GnRH signal an episodic pituitary release of LH and FSH was down-regulated to levels not compatible with fertility. The continuous treatment by GnRH-I or GnRH-I agonists was able, for example, to induce down- regulatory effects in bovine pituitary gonadotrophs [77 81]. The examination of mechanisms of LH and FSH biosynthesis revealed that the continuous treatment with a GnRH-I agonist might inuence gonadotropin biosynthesis by a post-transcriptional mechanism because the contents of both hormones were suppressed to a greater degree than their beta-subunit mRNAs [82]. Recent studies in which the release of FSHand LHwere examined in pituitary portal or sinus cavernosus blood samples have shown that, while there is a high degree of synchrony between the pulsatile release of GnRH-I and LH, FSH release is only associated with a small portion of the GnRH pulses [13]. There are many experimental results which indicate a different release pattern of LH and FSH during the estrous cycle of untreated animals but the underlying mechanisms are still unclear [52]. The existence of one mechanism for the different regulation of LH and FSH F. Schneider et al. / Theriogenology 66 (2006) 691709 695 by a single neuroendocrine factor seems to be contra- dictory. High-frequency GnRH pulses favour LH release, whereas low-frequency pulses favour FSH release. This discrepancy was the reason to assume that an additional peptide exists which releases specically FSH [83]. Among the natural GnRHs, both GnRH-II [84,85] and lGnRH-III [86] or a closely related peptide [46,87] have been suggested to be the putative FSH-RH but there is neither a study conrming the presence of GnRH-II in the pituitary portal blood [88] nor a consensus over the functioning of lGnRH-III as FSH- RH in mammals [11]. By applying a specic GnRH-I antagonist in two sheep models, another group [89] was able to demonstrate a constitutive component of GnRH- I-independent basal LH release after termination of pulses. But, more interestingly, a rst evidence was provided by the authors that an acute GnRH-I- independent component of episodic FSH secretion exists which may, probably be triggered by a selective GnRH-II effect or by a hypothalamic compound still unknown. In other studies [13,52], where a different packaging of both gonadotropins in storage granules within the gonadotrope cells was detected, constitutive pathways of FSH and basal LH release as well as a GnRH-regulated pathway of pulsatile LH release were also explored. The distribution of GnRH-I and its natural analogues in both the same and different neurons and brain areas may lead to the conclusion that there is a common or a sequential release of related peptides. The distinguished feature of GnRH-II is, for example, its wide distribution in extrahypothalamic regions of the brain compared with GnRH-I [21]. The more the interest is growing to analyze the specic release patterns and to discover the behavioral roles of GnRHs the more a need is arising to develop suitable models [22]. Models may, for example, involve animals that are energetically challenged by food restriction. Such animals showed increases in the number of GnRH-II immunoreactive cell bodies and ber dense area followed by a fast emptying of stored peptide plus showing behavioral activity after refeeding [31]. 4. Reception of GnRH-I and its variants Hypothalamic GnRH-I regulates the synthesis and secretion of LH and FSH on pituitary gonadotrophs through its receptor [90]. The density of the type-I GnRHR on gonadotrophs is changing during various stages of the estrous cycle [91]. Receptor concentrations have been reported to increase up to day 18 of the bovine estrous cycle [92] stimulated mainly by GnRH-I itself and E 2 . Developing ovarian follicles produce increasingly E 2 that substitutes the GnRH effect and maintains high abundance of GnRHR mRNA in the preovulatory period. It was discussed that P 4 exerts a suppressive inuence [91,93,94], therefore, maximal GnRHR expression and maximal sensitivity of gona- dotrophs to GnRH is probably triggered by decreased circulating concentrations of P 4 at luteolysis [95]. The presence of a P 4 -responsive element in the 5 0 -anking region of the human GnRHR suggests, however, the regulation of this gene by P 4 . As explored recently, the physiological effects of P 4 are mediated through two receptor forms, the truncated form PR-A and PR-B. Overexpression of PR-A was reported to decrease GnRHR promoter activity both in pituitary and placental cells but that of PR-B was found to exhibit a cell-dependent transcriptional activity, e.g. to decrease it only in pituitary cells [96]. From 1992/1993, since the initial isolation of the cDNAs encoding the type-I GnRHR of the mouse [97,98], rat [99,100], sheep [101,102], human [103,104], cattle [105], pig [106] and, following this, other species, a lot of studies were performed to describe the molecular structure and organization of the GnRHR gene. Mammalian pituitary type-I GnRHRs share often over 80% AA identity. The cDNA of the type-I GnRHR encodes, for example, a 327 AA protein in mouse and rat, and a Lys residue more is present in sheep and human [10]. Non-mammalian receptors show not more than 4247% identity to those of mammals and 5867% among each other, respectively [17]. The type-I GnRHR is a member of the G-protein- coupled receptor (GPCR) family which is characterized by an extracellular N terminus and an intracellular C terminus linked by seven transmembrane (7TM; TM1 TM7) helices. The helices are connected by each three extracellular and intracellular loops [91,107,108]. GPCRs comprise a large superfamily of proteins; more than 1000 different members of that are still known [109]. Receptor binding activates two specic GTP- binding proteins (Gq/G11), which stimulate increased phosphoinositol turnover by activating phospholipase C (PLC). This enzyme leads to the generation of several second messengers [110]. Among these, diacylglycerol (DG) and inositol 1,4,5-tris-phosphate (IP3) are critically important. DG leads to activation of protein kinase C (PKC), and IP3 releases Ca 2+ from intracel- lular pools [74]. Both events result in gonadotropin synthesis, which is realized across the stimulation of the steroidogenic factor 1 (SF-1) [111,112], followed by secretion of LH and FSH. It has been demonstrated that the GnRH signal transduction pathway involves an F. Schneider et al. / Theriogenology 66 (2006) 691709 696 increase in cAMP and an activation of members of the mitogen-activated protein kinase (MAPK) family [74,110]. To help understanding the molecular mechan- isms involved in transcriptional regulation of the receptor gene, the 5 0 ankingregionof the type-I GnRHRhas been isolated, and there were explored several DNA regions which are responsible for both basal expression and GnRH-I-mediated homologous regulation of this gene in pituitary cells [113]. The type-I GnRHR has a relatively short third intracellular loop, and it lacks a Cterminal tail [110]. Because the tail is unique among GPCRs, its loss during evolution should be discussed. The structural features described may be responsible for the relative resistance of the type-I GnRHR to rapid homologous receptor desensitization and slow internalization by GnRH-I agonist-induced phosphorylation or binding b- arrestin by sustained stimulation [114]. However, the presence of more than one forms of GnRH in the same species implies the co-evolution of cognate receptors. In all, three GnRH peptides and three cognate receptors have been yet identied with distinct distributions and functions [17]. Two or three different types of GnRHR have been indeed identied in non- mammalian species like sh and frog [20], but also in Macaca mulatta [115,116]. In contrast, only one functional GnRHR gene, the type-I GnRH gene, has been identied in humans. Some ndings suggested that a type-II GnRHR gene has arisen during vertebrate evolution, is also present but vestigial in the human due to the transcription of the opposite DNA strand to antisense RNA [117]. The gene encoding the type-II GnRHR is, however, functional in chimpanzee but partially or completely silenced in a range of other mammals [33]. Antisera to one domain of the human type-II receptor, for example, revealed immunoreactivity in pituitary and brain cells of the human, rhesus monkey, sheep and mouse [21]. The primate type-II GnRHR AA sequences share 60% identity with amphibian type-II GnRHRs and 40% identity with the human type-I GnRHR [88]. That means that the structure of monkey type-II GnRHR resembles more closely non-mammalian types of GnRHRs than mammalian type-I GnRHRs [20]. Like- wise, non-mammalian GnRHRs contain also a C- terminal cytoplasmatic tail, and both groups of receptors have conserved Asp 2.50 /Asp 7.49 residues, while mamma- lian GnRHRs contain Asn 2.50 /Asp 7.49 at these positions [118]. It was shown by mutation products of the mouse type-II receptor that Asp 7.49 in TM7 is an essential component of ligand-mediated receptor activation and the TM2 Asn 2.50 is essential for conguring and expression of the receptor [17]. Finally, non-mammalian and monkey type-II GnRHRs are more sensitive to GnRH-II than GnRH-I [30,119]. Type-II receptors are highly selective for GnRH-II, e.g. GnRH-II is approxi- mately 400-fold more potent at type-II GnRHR than type-I receptors [17] and has approximately 10% of the activity of GnRH-I at the type-I receptor [30], respectively. In addition to the gonadotropes, type-I GnRHRs are also expressed in many other tissues, e.g. breast, gonads, the central nervous system, and some neoplastic tissues [6,114,120123]. The presence of GnRH-I and type-I receptors in the gonads of various vertebrate species, including mammals, may reect a direct regulation of the gonads as an early evolved function, and the neuroendo- crine role in regulating the pituitary as a later evolutionary development [11]. However, unlike the hypothalamus and pituitary, the regulation of GnRH-I and its receptor in the ovary is poorly understood [12]. In human placenta, where GnRH-I is thought to playroles in both growth and function, the expression of type-I receptors is regulated by an autocrine mechanism [124]. Recently, it was shown, that GnRH-I and GnRH-II are coexpressed in the rst-trimester decidua, suggesting biological effects within and between maternal and fetal cellular compartments [125]. As mentioned before, the type-II GnRHR has been cloned from various vertebrate species, including New and Old World primates. The human gene homologue of this receptor is considered as vestigial receptor, as reported [117], is frame-shifted and has a different stop codon, and it appears that GnRH-II signalling occurs through the type-I receptor [17]. A growing number of extrapituitary GnRH-II actions in humans have been demonstrated although a full-length type-II receptor transcript has not yet been identied [115]. Likewise, it is absent from chimpanzee, cow, horse, sheep, rat and mouse in spite of its presence in other species, e.g. pig[11]. This challenges the questionif there is expressed a functional type-II receptor protein expression in cells lacking the type-I receptor. It was shown that the antiproliferative effect of GnRH-II on human cancer cells is not mediated through the type-I receptor like that of a GnRH antagonist [126]. The data are in accord with a report from[127] demonstrating that the human type-II GnRHR is functional, and its splice variant determines the direction of the cellular response to GnRH stimulation. More recently, an immunohisto- logical study using a polyclonal antiserum against the putative human GnRH-II receptor demonstrated the existence of a GnRH-II receptor-like protein in human placenta and in cancers of human reproductive organs [128]. The sequences of the pig and monkey type-II GnRHRs are 91% identical as well as their functional F. Schneider et al. / Theriogenology 66 (2006) 691709 697 properties, e.g. in terms of stimulating the IP3 production by GnRH-I and GnRH-II, respectively [30]. Interest- ingly, further variants of the type-II GnRHR exist in sheepandcattlewhich donot appear to encode functional 7TM GPCRs. Similar observations were made in human and pigs where receptor forms have been explored which showed a shortened structure (Fig. 3) [30,88,129,130]. 5. Hypophyseal and extrahypophyseal effects of natural GnRHs In invertebrates, which have no pituitary gland, the diversity of anatomical distribution patterns observed for GnRH or GnRH-like factors suggests that GnRHs may have multiple functions. One of them could be related to stimulation of reproduction by a direct action on the gonads [11,15,131]. Such functions explored for GnRH variants except GnRH-I in vertebrates would be evolutionarily old whereas the evolutionarily younger GnRH-I became responsive for specic tasks within the HPGaxis. The questions are if, inhigher vertebrates, both GnRH-I exerts functions other than stimulation of pituitary and if GnRHs exert functions included stimulationof gonadotropinrelease. Now, it is commonly accepted that GnRH-I is integrated in some important functions which fall into three categories [130]: gonadotropin secretion; sexual behavior; regulation of peripheral reproductive tissues. For a few decades, hypothalamic GnRH-I has been assumed to be sufcient to control synthesis and release of gonadotropins and sexual behavior, hence reproduc- tive function. Furthermore, it was suggested that the interactions of GnRH-I with ovarian steroids at the pituitary level are responsible for the nal regulation of LH and FSH release. As reviewed above, an increasing number of peptides have been observed, however, to affect gonadotropin activity during the following decades. None of these factors has gained an importance equal to that of GnRH-I. All data available suggest that differential synthesis and release of gonadotropins is caused by an altered pattern of pulsatile GnRH-I secretion and triggered by activation of pituitary type-I GnRHR [74]. Endogenous sources for GnRH and GnRH-like factors were found in manifold tissues. The fast destruction of the releasing hormone of hypothalamic origin by specic peptidases might lessen peripheral effects of them. However, GnRH-I inuences the functions of other organs, such as the breast, placenta, and ovary, in addition to its actions in the brain and pituitary. Extrapituitary actions of GnRH-I which have been manifold documented suggest that there is a functioning GnRH/GnRHR system in these organs. There is evidence for a paracrine/autocrine role of GnRH-I in the regulation of ovarian processes like follicular atresia and luteinization [132134]. Several ndings suggest that GnRH-I plays regulatory roles in processes prerequisite for decidualization and F. Schneider et al. / Theriogenology 66 (2006) 691709 698 Fig. 3. Topography of amino acid sequences of the three pig GnRH receptors type-I GnRHR (A), type-II GnRHR-5TM (B) and type-II GnRHR- 7TM (C). Adapted to Weesner and Matteri [106] and Neill et al. [130]. trophoblast invasion in humans [115]. Moreover, GnRH- I plays various neuromodulatory roles: it is present in the nervus terminalis, a neural plexus in the chemosensory mucosa of the nasal cavity, where it has obviously the function to modify olfactory information, perhaps at reproductively auspicious times [28]. The physiological roles of GnRH-I forms remain poorly understood until now[88]. Most information has been gained, however, on GnRH-II, where the specic conformation stabilizes the peptide compared to GnRH-I. The conservation of the GnRH-II structure >500 million years, unique location, and differential expression levels of GnRH-II the type-II receptor within and outside the brain in a distinct species suggest that it has a variety of reproductive and non- reproductive functions [8,10,21,43,88] (Table 2). As mentioned above, GnRH-II has a lowafnity to the type-I receptor. Therefore, it seems to be reasonable to reassess whether functions that have been ascribed to GnRH-I are might be caused by GnRH-II [130]. The neuromodulatory roles outlined for GnRH-I were also found for GnRH-II [18,125]. The conservation of the GnRH-II structure may indicate more a function as neurotransmitter which is involved in sexual behavior, than that of a hormone which induces gonadotropin release [21]. However, the only established function of GnRH-II is the inhibition of M currents (K + channels) in amphibian sympathetic ganglia mediated by binding to a receptor that is a homologue to the primate type-II GnRHR [21,134]. This function may support a role of GnRH-II as neuromodulator that seems to be a common and old function of GnRHvariants. It has been shown, for example, that these peptides are able to stimulate simultaneous spawning of individuals in a population, and in this way assure more successful fertilization in species that release their gametes into the water in which they live [15]. In vertebrates, however, there is a high co- localization of type-I receptors and type-II receptors in pituitary gonadotropes. Therefore, GnRH-I and GnRH-II may operate in concert to control the release of FSH and LH. Silencing of the type-II GnRHR can be, however, accommodated by GnRH-II signalling through the type-I receptor with a distinctly different prole [11]. Is one of the GnRHs able, however, to act as an specic FSH-releasing hormone (FSH-RH)? This issue became the subject of speculation from the beginning of the experimental GnRH story [83,135,136]. An FSH- RH must be capable for selectively stimulating FSH over LH or at least be a more potent releaser for FSH than of LH which should result in a discordant FSH secretion. GnRH-II has been designated as FSH-RH [84,85]. On the other hand there is no study conrming that the peptide is present in the pituitary portal blood [137]. The presence, however, must be seen as a prerequisite to exert a gonadotropin-releasing function. Other studies using rat hemi-pituitary cultures showed that only lGnRH-III stimulates FSH release at much lower doses than those required for LH [86,138]. More recent results conrmed the conclusion that lGnRH-III or a closely related peptide was really the wanted FSH- RH [46,87,139]. However, there is no consensus if lGnRH-III functions as FSH-RH or not in mammals [11] because others [29,140,141] were not able either to isolate lGnRH-III from various mammalian brains or to stimulate specically FSH secretion by this variant. Recently, it was summarized that lGnRH-III has no endocrine activity in mammals [142]. Therefore, it seems to be necessary to proof the question again in animal models, e.g. in sheep, in which the pituitary is disconnected from the brain. This model would eliminate problems in differentiating effects caused by other peptides [21]. Apart from the gonadotropin- releasing effects by GnRH-I to GnRH-III, and [Hyp 9 ]- GnRH, it was reported that wfGnRH(Table 1) increased gonadotropin/TSHalpha subunit RNA expression in dispersed rainbow trout pituitary cells [38] whereas most of GnRH variants showed a very low activity in stimulating gonadotropin release or ovulation [3]. For GnRH-II a role as an coordinator between food intake and energetic condition, respectively, and repro- ductive behavior was hypothesized. This function of GnRH-II may result in mating under optimized condi- tions [31,143]. It would be interesting to examine the level of type-II GnRHRs expressed in that species and to test these effects of GnRH-II in other mammals. Both GnRH systems, the GnRH-I/type-IGnRHR and the GnRH-II/type-II GnRHRsystem, likelyevolved together and act in a synergistic manner. Because nutrition and F. Schneider et al. / Theriogenology 66 (2006) 691709 699 Table 2 Tissue distribution and proposed physiological functions for GnRH-II Tissue Proposed function Central and peripheral nervous system Neuromodulation Mediobasal hypothalamus Control of gonadotropin secretion Limbic structures Stimulation of reproductive behavior Placenta Regulation of endocrine functions Endometrium Breast Ovary Tumors of the female reproductive tract Inhibition of cell proliferation Normal T cells, tumor T cells Stimulation of cell adhesion and migration Adapted to Limonta et al. [8]. reproduction are closely linked, it may be plausible that during evolution rst the more ancient GnRH form, i.e. GnRH-II, served all functions that coordinated energy and reproduction. Later GnRH-I usurped many of the non-behavioral functions as the interactions between the pituitary and gonads in mammals. It may be a disadvantage that most of the studies on the HPG axis were conducted in domesticated, well-fed laboratory mammals which may or may not even produce GnRH-II. Furthermore, it should be not surprising that results of examinations of natural GnRH variants in vivo and in vitro may differ from one species or cell type to another. While it is becoming evident that some species do not have a conventional type-II GnRHR system, specic GnRH-II responses have been observed in certain cell types. To solve this problem, the demonstration of a functional GnRH-II/type-II receptor system in cells lacking the type-I-receptor is needed [115]. Recently, such system was explored that exists in human endometrial, ovarian and breast cancer cells probably enabling the therapeutic use of GnRH-II to reduce proliferation of those not mediated by the type-I receptor [126]. 6. Use of GnRH-I and its natural forms in farm animals There is a growing interest to increase the efciency of reproductive performances of farm animals, towards of the inherited genetic potential [144]. The develop- ment of systems to control ovarian function and reproductive efciency with GnRHs and other phar- maceutical agents has to be founded on an under- standing of induced physiological effects and ability to capture any advantage by good management of the farm unit [145]. The pharmacological basis for the ther- apeutic use of GnRH derives from its physiological effect of stimulating gonadotropin release [146]. The use of GnRH-I and synthetic analogues is common in domestic animal production systems. The evaluation of agonist potency depends largely on the model used and wide varying potencies are reported for the same agonist. The design of analogues has focused on improving the receptor-binding and subsequent activa- tion for agonists as well as on their increased resistance to degradation by peptidases. In veterinary medicine the most widely used agonists are the natural decapeptide, buserelin and deslorelin [146]. Likewise, other syn- thetic analogues have reached practical importance (Table 3). The single treatment by a small dose of the GnRH-I agonist or its sustained release in low quantities will induce, after binding to the receptor and internalization of the ligand/receptor complex, a transient insensitivity to stimulation in gonadotrophs. The type-I GnRHR is replenished within several hours and this restores the responsiveness of cells to GnRH. Unlike that antago- nists may not provoke the initial stimulatory effect of F. Schneider et al. / Theriogenology 66 (2006) 691709 700 Table 3 Amino acid sequences of selected GnRH-I agonists and antagonists used/recommended for use in humans and farm animals Amino acid 1 2 3 4 5 6 7 8 9 10 GnRH-I pGlu His Trp Ser Tyr Gly Leu Arg Pro Gly.NH2 Agonists Lupron pGlu His Trp Ser Tyr D Leu Leu Arg Pro NEt Zoladex pGlu His Trp Ser Tyr D Ser (tBu) Leu Arg Pro Gly.NH2 Supprelin pGlu His Trp Ser Tyr D His (ImBzl) Leu Arg Pro Gly.NH2 Synarel pGlu His Trp Ser Tyr D Nal Leu Arg Pro Gly.NH2 Triptorelin pGlu His Trp Ser Tyr D Trp Leu Arg Pro Gly.NH2 Buserelin pGlu His Trp Ser Tyr D Ser (tBu) Leu Arg Pro NEt Goserelin pGlu His Trp Ser Tyr D Ser (tBu) Leu Arg Pro AzGly Deslorelin pGlu His Trp Ser Tyr D Trp Leu Arg Pro NEt Antagonists Cetrorelix D Nal D Cpa D Pal Ser Tyr D Cit Leu Arg Pro D Ala. NH2 Ganirelix D Nal D Cpa D Pal Ser Tyr D hArg (Et)2 Leu D hArg (Et)2 Pro D Ala. NH2 Abarelix D Nal D Cpa D Pal Ser N Me Tyr D Asn Leu Lys (iPr) Pro D Ala. NH2 Antide D Nal D Cpa D Pal Ser Lys (Nic) D Cit Leu Lys (iPr) Pro D Ala. NH2 Teverelix D Nal D Cpa D Pal Ser Tyr D hCit Leu Lys (iPr) Pro D Ala. NH2 FE 200486 D Nal D Cpa D Pal Ser Aph (Hor) D Aph (Cba) Leu Lys (iPr) Pro D Ala. NH2 Nal-Glu D Nal D Cpa D Pal Ser Arg D Glu (AA) Leu Arg Pro D Ala. NH2 Bold letters: primary structure of GnRH-I and identical amino acids in analogues. Adapted to Millar et al. [17]. agonists and their blocking effects are immediate but just as reversible [147]. Previously, one of the main objectives to use GnRH-I and its synthetic agonists was to induce in females reduced fertility or even infertility using the LH- releasing and ovulation-inducing properties. The development of pro-fertility treatments resulted in several therapies, e.g. induction of ovulation, treatment of cystic ovarian disease and prevention of embryonic mortality. Numerous studies have been carried out with GnRH-I and agonists in different climates, production systems, reproduction status, etc. and sometimes combined with other hormonal treatments. In this context it is sometimes difcult to draw general conclusions on treatment efcacy in several species [146]. For several reasons the situation in the GnRH- treated cattle needs special interest but conclusions are to drawn parallel for sheep, horses and pigs. GnRH-I agonists originally developed to treat infertility show paradoxically inhibited reproduction when given in high doses or even continuously. This effect is exploited in anti-fertility methods of treatment. There are, however, different ways that GnRH-I analogues can be employed to inhibit reproduction by direct suppression of the HPG axis at the level of the gonadotroph: (1) chronic administration of agonists causing down-regulation of type-I GnRHR and desen- sitization of pituitary gonadotrophs; (2) immunization against GnRH-I resulting in the neutralization of GnRH-I in the hypophyseal portal blood by antibodies and (3) the use of antagonists to block receptors to occupancy by endogenous GnRH-I [147]. Among the pro-fertility treatments the therapy of bovine cystic ovarian disease by GnRH was undertaken in numerous studies [145,148150]. Although com- monly used in veterinary practice the fertility of treated cattle remains very poor after stimulating ovulation/ luteinisation of a new follicle and luteinisation of the cyst. A better understanding of the syndrome is probably required to improve fertility and not only to restore normal fertility [146]. Another complex of treatments by GnRH-I is directed to the support of ovulation process. Data from treatments of various species underline the importance of additional GnRH on the day of insemination to improve the chances of successful pregnancy. It is the common aim of the treatment to stimulate luteinisation and early production of luteal progesterone [151155]. When comparing the effects of different studies it was summarized [146] that the lower the background fertility in the herd, the higher the percentage improvement. Given a satisfying fertility in the herd the results may be equivocally. In cattle but also in other species numerous experiments were performed to enhance the luteal function and improve the pregnancy rate by a GnRH treatment approximately during the periods of maternal recognition of pregnancy [156161]. Recently, it was summarized that the balance of different data suggests that post-insemination GnRH treatments are benecial but exact validations of physiological and environ- mental variables have to be executed in each treated species [146]. A further aim of GnRH treatment is directed to override the delayed resumption of ovarian cyclicity in cows post-partum. It was stated [162] that research on this topic seems to have lapsed in the last decade when real time ultrasound was available for on- farm diagnosis of ovarian status. The treatment of seasonally anestrous animals, e.g. sheep, by GnRH has reached only a limited importance although scientically solved by applying multiple low- dose injections of an agonist [163,164]. Reasons were seen in the necessity to prime the animals by progesterone to simulate a luteal-like period of cycle followed by the peptide treatment which will increase unfavourably the costs of treatment. Use of GnRH as an integral part of synchronising regimens where is given 7 days before PG an then again 4860 h after PG appears to be effective in increasing the synchrony of ovulation in controlled breeding programmes [165170]. Whereas the rst injection is important for the prolongation of luteal phases in those animals treated late in the cycle, the main synchronising effect seems result from the second GnRH injection. This injection advanced the timing of ovulation and the subsequent rise in progesterone concentrations by an average of 24 h relative to cows just receiving a GnRH- PG regimen [146]. The other complex of methods that use GnRH-I analogues is summarized as anti-fertility technologies. Long-term fertility control agents are of interest for the management of reproduction in humans, domestic animals and wildlife. This topic is important in the management of farm animals but from both the behavioral and fertility standpoint, as is the case with domestic dogs and cats [147]. A rst group of methods is using the paradox effect of continuous GnRH on reproductive function. The continuous availability of the peptide is reached mainly by depot formulations. The desensitization of the gonadotrophes is followed by a decline in ovarian and testicular functions, respectively. This phenomenon is extensively applied in clinical medicine for the treatment of a wide range of disease [12]. Depot GnRH-I agonists are now increasingly used in animal treatments [171174]. F. Schneider et al. / Theriogenology 66 (2006) 691709 701 Recently [147] it was reviewed that agonists when released over periods of some months showed a high contraceptive rate both in veterinary regimes to treat farm and domestic animals. The fertility control by GnRH-I agonists has some advantages when compared with traditional surgical sterilization methods. One advantage is that contraception is affected after a single injection without the need for use of adjuvants. Numerous studies demonstrated a positive relationship between the dose of agonist and the duration of suppression but the reasons are still unknown. Recent results indicated that a continuous inuence of a depot GnRH-I agonist over a period of more than 1 week will impair the development of bovine follicles and oocytes [175]. Moreover, a wide range of variation was observed between individual animals in the interval to resumption of oestrous cycles after treatment and in the function of testes, respectively. A recent review [176] discussed the effects observed in growing and mature boars of a long- acting agonist treatment. Results of various studies [177,178] suggested that the treatment may be an effective means of reducing the taint in boar meat. In contrast to the response detected in most other species results were described that a GnRH-I agonist treatment induced an increase in the reproductive function. The treatment may be, for example, effective to accelerate puberty in calves [176,179]. Other possibilities to control fertility by GnRHare the treatments by antagonists and the immunization against the peptide resulting in its neutralisation in the portal blood by antibodies. Both methods are in the phase of development but they may have potential. The immu- noneutralisation of endogenous GnRH-I may prove to be an useful management tool in keeping both female and male animals [176]. The method has the advantage that it does not have a stimulatory acute phase [180185]. One disadvantage of vaccination is, however, the inconsistent and variable immune response of treated animals. Novel types of anti-GnRHvaccines are nowunder development to reduce the variation. GnRH-I antagonists (Table 3) also inhibit the reproductive system through competition with endo- genous peptide but the doses required to block gonadotropin release are higher than that of the comparable agonist treatment [186191]. Efcient delivering systems or the development of non-peptide orally active antagonists are likely to replace agonists as they avoid the undesirable stimulation that precedes desensitization [12]. Until acceptable technologies are available, the use of GnRH-I antagonists is especially to recommend for short-term treatments, e.g. down- regulation of the pituitary during IVF treatment regimes [147]. In brief, GnRH-based methods to manage fertility in farm animals have potential but the widespread application of these technologies is limited to date. Compared with the possibilities to apply GnRH-I and its synthetic analogues knowledge is only scarce on possibilities for the natural GnRH-I analogues. The main reason is that the physiological roles of GnRH-II and its receptor, and the roles of other pairs, relative to GnRH-I and its receptor are unknown [30]. Also, other facts may contribute, like the poor uniformity of occurrence [192] and reception [33] of GnRHs in mammals which make the development of suitable models more difcult. It seems to be nearly impossible to evaluate in vivo-effects of GnRHs beside that of GnRH-I. From data available at present, the following hypotheses should be executed in various models: Natural GnRHs unlike GnRH-I present in farm animals are residues of a long developmental process. They have no or less independent importance for basic functions of mammalian reproduction. GnRHs may intensify GnRH-I-mediated effects within the HPG axis. The contributions of GnRHs are still unknown but may vary between species, periods of the reproductive cycle, tissues and environmental factors, etc. GnRHs like GnRH-II, lGnRH-III or GnRH-III have functions within the neuroendocrine regulation of reproduction distinct from GnRH-I functions as discussed for the specic release of FSH [84 87,139,193]. This is supported by the fact that chronic administration of a GnRH-I shows a differential response of pituitary gland and gonads to the medication [194], even in ruminants [156]. GnRHs unlike GnRH-I show specic effects which result from the past like the combination of external factors from the environment with neuroendocrine mechanisms of regulation of reproductive function. In mammals, where, for example, GnRH-II is expressed at signicantly higher levels outside the brain, the peptide may participate, more than GnRH-I [10] in the induction of mating behavior. Ovarian steroids and their antagonists were reported to affect differentially the expression of GnRH-I and GnRH- II in human granulosa cells at the transcriptional level [195]. Both GnRH-II [9] and lGnRH-III [142] showed a direct antiproliferative effect on various cancer cell lines. Superactive analogues of that may, therefore, useful in specic therapeutic regimes in humans, instead of long-term administered GnRH-I agonists F. Schneider et al. / Theriogenology 66 (2006) 691709 702 [9]. An inclusion of GnRHs in treatment schedules of farm animals seems to be possible. To execute the preceding hypotheses, some general premises should be realized. The rst step is to complete the listing of presence of various GnRH forms in one species, in one tissue or expressed in one cell type. Next, the spectrum of analytical methods to characterize highly specically the biosynthesis, release of single variants in vivo and in vitro, and reception has to be replenished. Thus, animal models have to be created which may demonstrate specic effects of GnRH variants independent on the other forms, in particular GnRH-I, which may effect negligible low [21]. However, the function of GnRH-II as coordinator between nutrition and reproduction [143] should be explored in experimental studies on animals fed at different levels. Generally, development and use of potent synthetic analogues (agonists and antagonists) of promising GnRHs-like [D-Ala 6 ]-GnRH-II and Trptor- elix-1 [20] and [D-Arg 6 ]-GnRH-II-aza-Gly(10)-NH2 [196] may contribute to the exploration of functions of non-mammalian GnRHs in mammals. On the basis of these diverse studies a further progress in the development of effective and animal friendly applica- tions for natural GnRHs might be expected. References [1] Matsuo H, Baba Y, Nair RMG, Arimura A, Schally AV. Structure of the porcine LH-and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun 1971;43:13349. [2] Amoss M, Burgus R, Blackwell R, Vale W, Fellows R, Guillemin R. Purication, amino acid composition and n- terminus of the hypothalamic luteinizing hormone releasing factor (lrf) of ovine origin. Biochem Biophys Res Commun 1971;44:20510. [3] Sherwood NM, Lovejoy DA, Coe IR. Origin of mammalian gonadotropin-releasing hormones. Endocr Rev 1993;14: 24154. [4] Casan EM, Raga F, Bonilla-Musoles F, Polan ML. Human oviductal gonadotropin-releasing hormone: possible implica- tions in fertilization, early embryonic development, and implantation. J Clin Endocrinol Metab 2000;85:137781. [5] Krsmanovic LZ, Martinez-Fuentes J, Arora KK, Mores N, Tomic M, Stojilkovic SS, et al. Local regulation of gonadotroph function by pituitary gonadotropin-releasing hormone. Endo- crinology 2000;141:118795. [6] Grundker C, Gunthert AR, Westphalen S, Emons G. Biology of the gonadotropin-releasing hormone system in gynaecological cancers. Euro J Endocrinol 2002;146:114. [7] Leung PC, Cheng CK, Zhu XM. Multi-factorial role of GnRH-I and GnRH-II in the human ovary. Mol Cell Endocrinol 2003;202:14553. [8] Limonta P, Moretti RM, Marelli MM, Motta M. The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans. Front Neuroen- docrinol 2003;24:27995. [9] Emons G, Grundker C, Gunthert AR, Westphalen S, Kavanagh J, Verschraegen C. GnRH antagonists in the treatment of gynecological and breast cancers. Endocrine Relat Cancer 2003;10:2919. [10] Kang SK, Choi KC, Yang HS, Leung PCK. Potential role of gonadotrophin-releasing hormone (GnRH-I) and GnRH-II in the ovary and the ovarian cancer. Endocrine Relat cancer 2003; 10:16977. [11] Guillemin R. Hypothalamic hormones a.k.a. hypothalamic releasing factors. J Endocrinol 2005;184:1128. [12] Millar RP. GnRHs and GnRH receptors. Anim Reprod Sci 2005;88:528. [13] Pawson AJ, McNeilly AS. The pituitary effects of GnRH. Anim Reprod Sci 2005;88:7594. [14] Sealfon SC, Weinstein H, Millar RP. Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr Rev 1997;18:180205. [15] Gorbman A, Sower SA. Evolution of the role of GnRH in animal (Metazoan) biology. Gen Comp Endocrinol 2003;134: 20713. [16] Amano M, Oka Y, Kitamura S, Ikuta K, Aida K. Ontogenetic development of salmon GnRHand chicken GnRH-II systems in the brain of masu salmon (Oncorhynchus masou). Cell Tissue Res 1998;293:42734. [17] Millar R, Lu Z-L, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR. Gonadotropin-releasing hormone receptors. Endocr Rev 2004;25:23575. [18] Okubo K, Aida K. Gonadotropin-releasing hormone gene products downregulate the expression of their neighboring genes that encode protein tyrosine phosphatases a and e. Biochem Biophys Res Commun 2003;312:5316. [19] Cheon KW, Lee HS, Parhar I, Kang IS. Expression of the second isoform of gonadotrophin-releasing hormone (GnRH- II) in human endometrium throughout the menstrual cycle. Molec Hum Reprod 2001;7:44752. [20] Maiti K, Li JH, Wang AF, Acharjee S, Kim WP, Im WB, et al. GnRH-II analogs for selective activation and inhibition of non- mammalian and type-II mammalian GnRH receptors. Mol Cells 2003;16:1739. [21] Millar RP. GnRH II and type II GnRH receptors. Trends Endocrinol Metab 2003;14:3543. [22] Ramakrishnappa N, Rajamahendran R, Lin YM, Leung PCK. GnRH in non-hypothalamic tissues. Anim Reprod Sci 2005; 88:95113. [23] Clarke IJ, Pompolo S. Synthesis and secretion of GnRH. Anim Reprod Sci 2005;88:2955. [24] Amano M, Takahashi A, Yamanome T, Okubo K, Aida K, Yamamori K. Molecular cloning of three cDNAs encoding different GnRHs in the brain of barn ounder. Gen Comp Endocrinol 2002;126:32533. [25] Kleine B, Kienle A, Poettich M, Wolfahrt S, Jarry H, Rossma- nith WG. Analysis of ultrashort feedback regulation in human placental synthesis and secretion of GnRH by human tropho- blastic cells. Horm Metab Res 2000;32:21623. [26] Rissman EF. Behavioral regulation of gonadotropin-releasing hormone. Biol Reprod 1996;54:4139. [27] Bless EP, Walker HJ, Yu KW, Knoll JG, Moenter SM, Schwarting GA, et al. Live view of gonadotropin-releasing hormone containing neuron migration. Endocrinology 2005; 146:4638. F. Schneider et al. / Theriogenology 66 (2006) 691709 703 [28] Wirsig-Wiechmann CR. Function of gonadotropin-releasing hormone in olfaction. Keio J Med 2001;50:815. [29] Montaner AD, Mongiat L, Lux-Lantos VAR, Park M, Fischer WH, Craig AG, et al. Structure and biological activity of gonadotropin-releasing hormone isoforms isolated from rat and hamster brains. Neuroendocrinology 2001;74:20212. [30] Neill JD. Minireview: GnRH and GnRH receptor genes in the human genome. Endocrinology 2002;143:73743. [31] Temple JL, Millar RP, Rissman EF. An evolutionarily con- served form of gonadotropin-releasing hormone coordinates energy and reproductive behavior. Endocrinology 2003;144: 139. [32] Hiney JK, Sower SA, Yu WH, McCann SM, Dees WL. Gonadotropin-relasing hormone neurons in the preoptic- hypothalamic region of the rat contain lamprey gonadotro- pin-releasing hormone III, mammalian luteinizing hormone- releasing hormone, or both peptides. Proc Natl Acad Sci USA 2002;99:238691. [33] Morgan K, Millar RP. Evolution of GnRH ligand precursors and GnRH receptors in protochordate and vertebrate species. Gen Comp Endocrinol 2004;139:1917. [34] Iwakoshi E, Takuwa-Kuroda K, Fujisawa Y, Hisada M, Ukena K, Tsutsui K, et al. Isolation and characterization of a GnRH- like peptide from octopus vulgaris. Biochem Biophys Res Commun 2002;291:118793. [35] Gautron JP, Pattou E, Bauer K, Kordon C. Preferential dis- tribution of C-terminal fragments of [hydroxyproline9]LHRH in the rat hypocampus and olfactory bulb. Neuroendocrinology 1993;58:24050. [36] Montaner AD, Park M, Fischer WH, Craig AG, Chang JP, Somoza GM, et al. Primary structure of a novel gonadotropin- releasing hormone in the brain of teleost, pejerrey. Endocrinol- ogy 2001;142:145360. [37] Yamanaka C, Lebrethon MC, Vandersmissen E, Gerard A, Purnelle G, Lemaitre M, et al. Early prepubertal ontogeny of pulsatile gonadotropin-releasing hormone (GnRH) secretion: I. Inhibitory autofeedback control through prolyl endopeptidase degradation of GnRH. Endocrinology 1999;140:460915. [38] Adams BA, Vickers ED, Warby C, Park M, Fischer WH, Craig AG, et al. Three forms of gonadotropin-releasing hormone, including a novel form, in a basal salmonid, Coregonus clu- peaformis. Biol Reprod 2002;67:2329. [39] Adelman JP, Mason AJ, Hayick JS, Seeburg PH. Isolation of the gene and hypothalamic cDNA for the common precursor of gonadotropin-releasing hormone and prolactin-inhibiting fac- tor in human and rat. Proc Natl Acad Sci USA1986;83:17983. [40] White RB, Eisen JA, Kasten TL, Fernald RD. Second gene for gonadotropin-releasing hormone in humans. Proc Natl Acad Sci USA 1998;95:3059. [41] Lescheid DW, Terasawa E, Abler LA, Urbanski HF, Warby CM, Millar RP, et al. A second form of gonadotropin-releasing hormone (GnRH) with characteristics of chicken GnRH-II is present in the primate brain. Endocrinology 1997;138: 561829. [42] Densmore VS, Urbanski HF. Relative effect of gonadotropin- releasing hormone (GnRH)-I and GnRH-II on gonadotropin release. J Clin Endocrinol Metab 2003;88:212634. [43] Pawson AJ, Morgan K, Maudsley SR, Millar RP. Type II gonadotrophin-releasing-hormone (GnRH-II) in reproductive biology. Reproduction 2003;126:2718. [44] Kasten TL, White SA, Norton TT, Bond CT, Adelman JP, Fernald RD. Characterization of two newpreproGnRHmRNAs in the tree shrew: rst evidence for mesencephalic GnRH expression in a placental mammal. Gen Comp Endocrinol 1996;104:719. [45] Rissman EF, Alones V, Craig-Veit CB, Millam JR. Distribution of chicken II gonadotropin-releasing hormone in mammalian brain. J Comp Neurol 1995;357:52431. [46] Yu WH, Karanth S, Sower SA, Parlow AFP, McCann SM. The similarity of FSH-releasing factor to lamprey gonadotropin- releasing hormone III (l-GnRH-III). Proc Soc Exper Biol Med 2000;224:8792. [47] Yahalom D, Chen A, Ben-Aroya N, Rahimipour S, Kaga- novsky E, Okon E, et al. The gonadotropin-releasing hor- mone family of neuropeptides in the brain of human, bovine and rat; identication of a third isoform. FEBS Lett 1999; 463:28994. [48] Moenter SM, DeFazio RA, Pitts GR, Nunemaker CS. Mechan- isms underlying episodic gonadotropin-releasing hormone secretion. Front Neuroendocrinol 2003;24:7993. [49] Piva F, Zanisi M, Motta M, Martini L. Ultrashort control of hypothalamic hormones secretion: a history. J Endocrinol Invest 2004;27(Suppl. 6):6872. [50] McCann SM, Kimura M, Walczewska A, Karranth S, Rettori V, Yu WH. Hypothalamic control of FSH and LH by FSH-RF, LHRH, cytokines, leptin and nitric oxide. Neuroimmunomo- dulation 1998;5:193202. [51] Nunemaker CS, Straume M, Defazio RA, Moenter SM. Gona- dotropin-releasing hormone neurons generate interacting rhythms in multiple time domains. Endocrinology 2003;144: 82331. [52] McNeilly AS, Crawford JL, Taragnat C, Nicol L, McNeilly JR. The differential secretion of FSH and LH: regulation through genes, feedback and packaging. Reprod Suppl 2003;61:463 76. [53] Weesner GD, Harms PG, McArthur NH, Wilson JM, Forrest DW, Wu TJ, et al. Luteinizing hormone-releasing hormone gene expression in the bovine brain: anatomical localiza- tion and regulation by ovarian state. Biol Reprod 1993;49: 4316. [54] Karsch FJ, Dahl GE, Evans NP, Manning JM, Mayeld KP, Moenter SM, et al. Seasonal changes in gonadotropin-reelasing hormone secretion in the ewe: alteration in response to the negative feedback action of estradiol. Biol Reprod 1999;49: 137783. [55] Nett TM, Turzillo AM, Baratta M, Rispoli LA. Pituitary effects of steroid hormones on secretion of follicle-stimulating hor- mone and luteinizing hormone. Domest Anim Endocrinol 2002; 23:3342. [56] Barb CR. The brain-pituitary-adipocyte axis: role of leptin in modulating neuroendocrine function. J Anim Sci 1999;77: 124957. [57] Dobson H, Smith RF. What is stress, and how does it affect reproduction? Anim Reprod Sci 2000;6061:74352. [58] Wauters M, Considine RV, Van Graal LF. Human leptin: from an adipocyte hormone to an endocrine mediator. Eur J Endo- crinol 2000;143:293311. [59] Tilbrook AJ, Turner AI, Clarke IJ. Stress and reproduction: central mechanisms and sex differences in non-rodent species. Stress 2002;5:83100. [60] Barb CR, Barrett JB, Kraeling RR. Role of leptin in modulating the hypothalamic-pituitary axis and luteinizing hormone secre- tion in the prepuberal gilt. Domest Anim Endocrinol 2004;26: 20114. F. Schneider et al. / Theriogenology 66 (2006) 691709 704 [61] Breen KM, Karsch FJ. Does cortisol inhibit pulsatile luteinizing hormone secretion at the hypothalamic or pituitary level? Endocrinology 2004;145:6928. [62] Schneider F, Brussow KP, Kanitz E, Otten W, Tuchscherer A. Maternal reproductive hormone levels after repeated ACTH application to pregnant gilts. Anim Reprod Sci 2004;81: 31327. [63] Chang WJ, Barb CR, Kraeling RR, Rampacek GB, Leshin LS. Involvement of the central noradrenergic system in opioid modulation of luteinizing hormone and prolactin secretion in the pig. Biol Reprod 1993;49:17680. [64] Herbison AE. Noradrenergic regulation of cyclic GnRH secre- tion. Rev Reprod 1997;2:116. [65] Hoffman GE, Berghorn KA. Gonadotropin-releasing hormone neurons: their structure and function. Sem Reprod Endocrinol 1997;15:517. [66] Malpaux B, Thiery JC, Chemineau P. Melatonin and seasonal control of reproduction. Reprod Nutr Dev 1999;39:35566. [67] Ortmann O, Diedrich K. Pituitary and extrapituitary actions of gonadotropin-releasing hormone and its analogues. Hum Reprod Suppl 1999;1:194206. [68] Ziecik AJ, Sienkiewicz W, Okrasa S, Kalamarz H, Lakomy M, Kraeling RR. Concentration and distribution of neuropeptide Y, galanin, b-endorphin, vasoactive intestinal peptide and gona- dotropin-releasing hormone in the hypothalamus of gilts during oestrogen-induced surge secretion of luteinizing hormone. Reprod Dom Anim 1999;34:47787. [69] Prunier A, Quesnel H. Nutritional inuences on the hormonal control of reproduction in female pigs. Livest Prod Sci 2000; 63:116. [70] McCann SM, Kimura M, Karanth S, Yu W, Rettori V. Role of nitric oxide in the neuroendocrine response to cytokines. In: Gaillard RC, editor. Neuroendocrine-immune interac- tions, vol. 29. Basel: Karger. Front Horm Res; 2002. p. 11729. [71] Evans JJ. Modulation of gonadotropin levels by peptides acting at the anterior pituitary gland. Endocr Rev 1999;20:4667. [72] Kaiser UB, Conn PM, Chin WW. Studies of gonadotropin- releasing hormone (GnRH) action using GnRH receptor- expressing pituitary cell lines. Endocr Rev 1997;18:4670. [73] Dalkin AC, Burger LL, Aylor AW, Haisenleder DJ, Workman LJ, Cho S, et al. Regulation of gonadotropin subunit gene transcription by gonadotropin-releasing hormone: measure- ment of primary transcript ribonucleic acids by quantitative reverse transcription-polymerase chain reaction assays. Endo- crinology 2001;142:13946. [74] Burger LL, Haisenleder DJ, Dalkin AC, Marshall JC. Regula- tion of gonadotropin subunit gene transcription. J Mol Endo- crinol 2004;33:55984. [75] De Koning J, Lambalk CB, Helmerhorst FM, Helder MN. Is GnRH self-priming an obligatory feature of the reproductive cycle? Hum Reprod 2001;16:20914. [76] Caraty A, Antoine C, Delaleu B, Locatelli A, Bouchard P, Gautron JP, et al. Nature and bioactivity of releasing-hormone (GnRH) secreted during the GnRH surge. Endocrinology 1995; 136:345260. [77] DOcchio MJ, Gifford DR, Earl CR, Weatherly T, von Rechen- berg W. Pituitary and ovarian responses of post-partum acyclic beef cows to continuous long-term GnRH and GnRH agonist treatment. J Reprod Fert 1989;85:495502. [78] DOcchio MJ, Fordyce G, Whyte TR, Jubb TF, Fitzpatrick LA, Cooper NJ, et al. Use of GnRH agonist implants for long-term suppression of fertility in extensively managed heifers and cows. Anim Reprod Sci 2002;74:15162. [79] Gong JG, Campbell BK, Bramley TA, Gutierrez CG, Peters AR, Webb R. Suppression in the secretion of follicle-stimulat- ing hormone and luteinizing hormone, and ovarian follicle development in heifers continuously infused with a gonado- tropin-releasing hormone agonist. Biol Reprod 1996;55:6874. [80] Viczarra JA, Wettemann RP, Braden DT, Turzillo AM, Nett TM. Effect of gonadotropin-releasing hormone (GnRH) pulse frequency on serum and pituitary concentrations of luteinizing hormone and follicle-stimulating hormone, GnRH receptors, and messenger ribonucleic acid for gonadotropin subunits in cows. Endocrinology 1997;138:594601. [81] Schneider F, Bellmann A, Becker F, Bambang Poernomo S, Rehfeldt C, Nurnberg G, et al. Gonadotropin release in peri- ovulatory heifers after GnRH analogs measured by two types of immunoassays. Exp Clin Endocrinol Diabetes 2002;110: 23544. [82] Aspden WJ, Jackson A, Trigg TE, DOcchio MJ. Pituitary expression of LHbeta- and FSHbeta-subunit mRNA, cellular distribution of LHbeta-subunit mRNA and LH and FSH synth- esis during and after treatment with a gonadotrophin-releasing hormone agonist in heifers. Reprod Fertil Dev 2003;15:14956. [83] Padmanabhan V, McNeilly AS. Is there an FSH-releasing factor? Reproduction 2001;121:2130. [84] Lumpkin MD, Moltz JH, Yu WH, Samson WK, McCann SM. Purication of FSH-releasing factor: its dissimilarity from LHRH of mammalian, avian and piscian origin. Brain Res Bull 1987;18:1758. [85] Millar R, Lowe S, Conklin D, Pawson A, Maudsley S, Troskie B, et al. A novel mammalian receptor for the evolutionarily conserved type II GnRH. Proc Nat Acad Soc USA 2001; 98:963741. [86] Yu WH, Karanth S, Walczewska A, Sower SA, McCann SM. A hypothalamic follicle stimulating hormone releasing decapep- tide in the rat. Proc Natl Acad Sci USA 1997;94:9499503. [87] Dees WL, Dearth RK, Hooper RN, Brinsko SP, Romano JE, Rahe H, et al. Lamprey gonadotropin-releasing hormone-III selectively follicle stimulating hormone in the bovine. Domest Anim Endocrinol 2001;20:27988. [88] Gault PM, Morgan K, Pawson AJ, Millar RP, Lincoln GA. Sheep exhibit novel variations in the organization of the mammalian type II gonadotropin-releasing hormone receptor gene. Endocrinology 2004;145:236274. [89] Padmanabhan V, Brown MB, Dahl GE, Evans NP, Karsch FJ, Mauger DT. Neuroendocrine control of follicle-stimulating hormone (FSH) secretion: III. Is there a gonadotropin-releasing hormone-independent component of episodic FSH secretion in ovariectomized and luteal phase ewes? Endocrinology 2003; 144:138092. [90] Gharib SD, Wierman ME, Shupnik MA, Chin WW. Molecular biology of the pituitary gonadotropins. Endocr Rev 1990; 11: 17799. [91] Rispoli LA, Nett TM. Pituitary gonadotropin-releasing hor- mone (GnRH) receptor: Structure, distribution and regulation of expression. Anim Reprod Sci 2005;88:5774. [92] Nett TM, Cermak D, Braden T, Manns J, Niswender GD. Receptors for GnRH and estradiol and pituitary content of gonadotropins in beef cows. I. Changes during the estrous cycle. Domest Anim Endocrinol 1987;4:12332. [93] Wu JC, Sealfon SC, Miller WL. Gonadal hormones and gonadotropin-releasing-hormone (GnRH) alter messenger F. Schneider et al. / Theriogenology 66 (2006) 691709 705 ribonucleic acid levels for GnRH receptors in sheep. Endocri- nology 1994;134:184650. [94] Brooks J, McNeilly AS. Regulation of gonadotrophin-releasing hormone receptor expression in the ewe. Anim Reprod Sci 1996;42:8998. [95] Turzillo AM, Nett TM. Regulation of GnRH receptor gene expression in sheep and cattle. J Reprod Fertil Suppl 1999; 54:7586. [96] Cheng KW, Cheng CK, Leung PC. Differential role of PR-A and PR-B isoforms in transcription regulation of human GnRH receptor gene. Mol Endocrinol 2001;15:207892. [97] Reinhart J, Mertz LM, Catt KJ. Molecular cloning and expres- sion of the rat pituitary gonadotropin-releasing hormone recep- tor. J Biol Chem 1992;267:212814. [98] Tsutsumi M, Zhou W, Millar RP, Mellon PL, Roberts JL, Flanagan CA, et al. Cloning and functional expression of a mouse gonadotropin-releasing hormone receptor. Mol Endo- crinol 1992;6:11639. [99] Eidne KA, Sellar RE, Couper G, Anderson L, Taylor PL. Molecular cloning and characterisation of the rat pituitary gonadotropin-releasing hormone (GnRH) receptor. Mol Cell Endocrinol 1992;90:R59. [100] Kaiser UB, Zhao D, Cardona GR, Chin WW. Isolation and characterization of cDNAs encoding the rat pituitary gonado- tropin-releasing hormone receptor. Biochem Biophys Res Commun 1992;189:164552. [101] Brooks J, Taylor PL, Saunders PTK, Eidne KA, Struthers WJ, McNeilly AS. Cloning and sequencing of the sheep pituitary gonadotropin-releasing hormone receptor and changes in expression of its mRNA during the estrous cycle. Mol Cell Endocrinol 1993;94:R237. [102] Illing N, Jacobs GF, Becker II, Flanagan CA, Davidson JS, Eales A, et al. Comparative sequence analysis and functional characterization of the cloned sheep gonadotropin-releasing- hormone receptor reveal differences in primary structure and ligand specicity among mammalian receptors. Biochem Bio- phys Res Commun 1993;196:74551. [103] Chi L, Zhou W, Prikhozhan A, Flanagan C, Davidson JS, Golembo M, et al. Cloning and characterization of the human GnRH receptor. Mol Cell Endocr 1993;91:R16. [104] Kakar SS, Musgrove LC, Devor DC, Sellers JC, Neill JD. Cloning, sequencing, and expression of human gonadotropin releasing hormone (GnRH) receptor. Biochem Biophys Res Commun 1992;30:28995. [105] Kakar SS, Rahe CH, Neill JD. Molecular cloning, sequencing, and characterizing the bovine receptor for gonadotropin releas- ing hormone (GnRH). Domest Anim Endocrinol 1993;10: 33542. [106] Weesner GD, Matteri RL. Nucleotide sequence of luteinizing hormone-releasing hormone (LHRH) receptor cDNA in the pig pituitary (Rapid Communication). J Anim Sci 1994;72:1911. [107] Wess J. G-protein-coupled receptors: molecular mechanisms involved in receptor activation and selectivity of G protein recognition. FASEB J 1997;11:34654. [108] Ji TH, Grossmann M, Ji I. G-protein coupled receptors. I. Diversity of receptor-ligand interactions. J Biol Chem 1998; 273:17299302. [109] Gether U. Uncovering molecular mechanisms involved in activation of G protein coupled receptors. Endocr Rev 2000; 21:90113. [110] Naor Z, Millar RP, Seger R. Signaling of GnRH receptor in pituitary gonadotrophs. In: GnRH analogs in human reproduc- tionstate of the art 2005 Parthenon Publishing Group; 2005. p. 113. [111] Haisenleder DJ, Yasin M, Dalkin AC, Gilrain C, Marshall JC. GnRH regulates steroidogenic factor-1 (SF-1) gene expression in the rat pituitary. Endocrinology 1996;137:571922. [112] Halvorson LM. Transcriptional regulation of the LH beta gene by gonadotropin-releasing hormone and the protein kinase C system. Vitam Horm 2000;60:195227. [113] Cheng KW, Leung PC. The expression, regulation and signal transduction pathways of the mammalian gonadotropin-releas- ing hormone receptor. Can J Physiol Pharmacol 2000;78:1029 52. [114] McArdle CA, Franklin J, Green L, Hislop JN. Signalling, cycling and desensitisation of gonadotrophin-releasing hor- mone receptors. J Endocr 2002;173:111. [115] Cheng CK, Leung PC. Molecular biology of gonadotropin- releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr Rev 2005;26:283306. [116] Neill JD, Duck LW, Sellers JC, Musgrove LC. A gonado- tropin-releasing hormone (GnRH) receptor specic for GnRH II in primates. Biochem Biophys Res Commun 2001;282: 10128. [117] Millar R, Conklin D, Lofton-Day C, Hutchinson E, Troskie B, Illing N, et al. A novel human GnRH receptor homolog gene: abundant and wide tissue distribution of the antisense tran- script. J Endocrinol 1999;162:11726. [118] Flanagan CA, Millar RP, Illing N. Advances in understanding gonadotrophin-releasing hormone receptor structure and ligands interactions. Rev Reprod 1997;2:11320. [119] Wang L, Bogerd J, Choi HS, Seong JY, Soh JM, Chun SY, et al. Three distinct types of GnRH receptor characterized in the bullfrog. Proc Natl Acad Soc USA 2001;98:3616. [120] Bull P, Morales P, Huyser C, Socias T, Castellon EA. Expres- sion of GnRH receptor in mouse and rat testicular germ cells. Mol Hum Reprod 2000;6:5826. [121] Stojilkovic SS, Reinhart J, Catt KJ. Gonadotropin releasing hormone receptors: structure and signal transduction pathways. Endocr Rev 1994;15:46299. [122] Bauer-Dantoin AC, Jameson JL. Gonadotropin-releasing-hor- mone messenger ribonucleic acid expression in the ovary during the rat estrous cycle. Endocrinology 1995;136:44328. [123] Kakar SS, Grizzle WE, Neill JD. The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Endocrinology 1995; 106:1459. [124] Wolfahrt S, Kleine B, Jarry H, Rossmanith WG. Endogenous regulation of the GnRH receptor by GnRH in the placenta. Mol Hum Reprod 2001;7:8995. [125] Chou CS, Beristain AG, MacCalman CD, Leung PC. Cellular localization of gonadotropin-releasing hormone (GnRH) I and GnRH II in rst-trimester human placenta and deciduas. J Clin Endocrinol Metab 2004;89:145966. [126] Grundker C, Gunthert AR, Millar RP, Emons G. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effect of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab 2002;87:142730. [127] Enomoto M, Endo D, Kawashima S, Park MK. Human type II GnRH receptor mediates effects of GnRH on cell proliferation. Zool Sci 2004;21:76370. [128] Eicke N, Gunthert AR, Viereck V, Siebold D, Behe M, Becker T, et al. GnRH-II receptor-like antigenicity in human placenta F. Schneider et al. / Theriogenology 66 (2006) 691709 706 and in cancers of human reproductive organs. Eur J Endocrinol 2005;153:60512. [129] Morgan K, Conklin D, Pawson AJ, Sellar R, Ott TR, Millar RP. A transcriptionally active human type II gonadotropin-releas- ing hormone receptor gene homolog overlaps two genes in the antisense orientation on chromosome 1q. 12. Endocrinology 2003;144:42336. [130] Neill JD, Musgrove LC, Duck LW. Newly recognized GnRH receptors: function and relative role. Trends Endocrinol Metab 2004;15:38392. [131] Enomoto M, Park MK. GnRH as a cell proliferation regulator: mechanism of action and evolutionary implications. Zool Sci 2004;21:100513. [132] Whitelaw PF, Eidne KA, Sellar R, Smyth CD, Hillier SG. Gonadotropin-releasing hormone receptor messenger ribonu- cleic acid expression in rat ovary. Endocrinology 1995;136: 1729. [133] Canipari R. Oocyte-granulosa cell interactions. Hum Reprod Update 2000;6:27989. [134] Jones SW. Chicken II luteinizing hormone-releasing hormone inhibits the M-current of bullfrog sympathetic neurons. Neu- rosci Lett 1987;80:1804. [135] Igarashi M, McCann SM. A hypothalamic follicle stimulating hormone releasing factor. Endocrinology 1964;79:44652. [136] Schally AV, Arimura A, Redding TW, Debeljuk L, Carter W, DuPont A, et al. Re-examination of porcine and bovine hypothalamic fractions for additional luteinizing and follicle stimulating hormone-releasing activities. Endocrinology 1976; 98:38091. [137] Gault PM, Maudsley S, Lincoln GA. Evidence that gonado- tropin-releasing hormone II is not a physiological regulator of gonadotropin secretion in mammals. J Neuroendocrinol 2003; 15:8319. [138] McCann SM, Yu WH. FSH-releasing peptides. US Patent 6,300,471 (2001). [139] McCann SM, Karanth S, Mastronardi CA, Dees WL, Childs G, Miller R, et al. Control of gonadotropin secretion by follicle-stimulating hormone-releasing factor, luteinizing hormone-releasing hormone, and leptin. Arch Med Res 2001;32:47685. [140] Kovacs M, Seprodi J, Koppan M, Horvath JE, Vincze B, Teplan I, et al. Lamprey gonadotropin hormone-releasing hormone-III has no selective follicle-stimulating hormone-releasing effect in rats. J Neuroendocrinol 2002;14:64755. [141] Amstalden M, Zieba DA, Garcia MR, Stanko RL, Welsh Jr TH, Hansel WH, et al. Evidence that lamprey GnRH-III does not release FSH selectively in cattle. Reproduction 2004;127: 3543. [142] Heredi-Szabo K, Lubke J, Toth G, Murphy RF, Lovas S. Importance of the central region of lamprey gonadotropin- releasing hormone III in the inhibition of breast cancer cell growth. Peptides 2005;26:41922. [143] Kauffman AS, Rissman EF. The evolutionarily conserved gonadotropin-releasing hormone II modies food intake. Endo- crinology 2004;145:68691. [144] Pell JM, Aston R. Principles of immunomodulation. Livestock Prod Sci 1995;42:12333. [145] Thatcher WW, Drost M, Savio JD, Macmillan KL, Entwistle KW, Schmitt EJ, et al. New clinical uses of GnRH and its analogues in cattle. Anim Reprod Sci 1993;33:2749. [146] Peters AR. Veterinary clinical application of GnRHquestions of efcacy. Anim Reprod Sci 2005;88:15567. [147] Herbert CA, Trigg TE. Applications of GnRHin the control and management of fertility in female animals. Anim Reprod Sci 2005;88:14153. [148] Kittok RJ, Britt JH, Convey EM. Endocrine response after GnRH in luteal phase cows and cows with follicular cysts. J Anim Sci 1973;37:9859. [149] Cantley TC, Garverick HA, Bierschwal CJ, Martin CE, Young- quist RS. Hormonal responses of dairy cows with ovarian cysts to GnRH. J Anim Sci 1975;41:166673. [150] Bartolome JA, Sozzi A, McHale J, Melendez P, Arteche ACM, Silvestre FT, et al. Resynchronisation of ovulation and timed insemination in lactating dairy cows, II. assigning protocols according to stages of the estrous cycle, or presence of ovarian cysts or anestrus. Theriogenology 2005;63:162842. [151] Hyland JH, Wright PJ, Clarke IJ, Carson RS, Langsford DA, Jeffcot LB. Infusion of gonadotrophin-releasing hormone (GnRH) induces ovulation and fertile oestrus in mares during seasonal anoestrus. J Reprod Fertil Suppl 1987;35:21122. [152] Mumford EL, Squires EL, Jochle W, Harrison LA, Nett TM, Trigg TE. Use of deslorelin short-term implants to induce ovulation in cycling mares during three consecutive estrous cycles. Anim Reprod Sci 1995;39:12940. [153] Brussow KP, Jochle W, Huhn U. Control of ovulation with a GnRH analog in gilts and sows. Theriogenology 1996;46:925 34. [154] Chebel R, Santos JEP, Cerri RLA, Juchem S, Galvao KN, Thatcher WW. Effect of resynchronization with GnRH on day 21 after articial insemination on pregnancy rate and pregnancy loss in lactating dairy cows. Theriogenology 2003;60:138999. [155] Ambrose JD, Pires MF, Moreira F, Diaz T, Binelli M, Thatcher WW. Inuence of deslorelin (GnRH-agonist) implant on plasma progesterone, rst wave dominant follicle and preg- nancy in dairy cattle. Theriogenology 1998;50:115770. [156] Davis TL, Mussard ML, Jiminez-Severiano H, Enright WJ, Kinder JE. Chronic treatment with an agonist of gonadotropin- releasing hormone enhances luteal function in cattle. Biol Reprod 2003;69:398403. [157] Hampton JH, Bader JF, Lamberson WR, Smith MF, Youngquist RS, Garverick HA. Gonadotropin requirements for dominant follicle selection in GnRH-agonist treated cows. Reproduction 2004;127:695703. [158] Beck NFG, Peters AR, Williams SP. The effect of GnRH analogue (buserelin) treatment on day 12 post mating on the reproductive performance of ewes. Anim Prod 1994;58:2437. [159] Peters AR, Martinez TA, Cook AJ. A meta-analysis of studies of the effect of GnRH 11-4 days after insemination on preg- nancy rates in cattle. Theriogenology 2000;54:131727. [160] Newcombe JR, Martinez TA, Peters AR. The effect of the gonadotropin-releasing hormone analog, buserelin, on preg- nancy rates in horses and pony mares. Theriogenology 2001; 55:161931. [161] Unger C, Schneider F, Hoppen HO, Becker F, Nurnberg G, Kanitz W. Pregnancy rates in mares after application of gona- dotropin releasing hormone analogue, Buserelin, in warmblood mares. Theriogenology 2002;58:6358. [162] Yavas Y, Walton JS. Induction of ovulation in post partum suckled beef cows: a review. Theriogenology 2000;54:123. [163] Schneider F, Rehbock F. Induction of fertile cycles in the Blackhead sheep during the anoestrus period. Arch AnimBreed 2003;46:4761. [164] Bartlewski PM, Aravindakshan J, Beard AP, Nelson ML, Batiasta-Arteaga S, Cook J, et al. Effects of medroxyproges- F. Schneider et al. / Theriogenology 66 (2006) 691709 707 terone acetate (MAP) on ovarian antral follicle development, gonadotrophin secretion and response to ovulation induction with gonadotrophin-releasing hormone (GnRH) in seasonally anoestrous ewes. Anim Reprod Sci 2004;81:6375. [165] Burke JM, De La Sota RL, Risco CA, Staples CR, Schmitt EJP, Thatcher WW. Evaluation of timed insemination using a gona- dotropin-releasing hormone agonist in lactating dairy cows. J Dairy Sci 1996;79:138593. [166] Stevenson JS, Kobayashi Y, Thompson KE. Reproductive performance of dairy cows in various programmed breeding systems including Ovsynch and combinations of gonadotropin- releasing hormone and prostaglandin F2. J Dairy Sci 1999;99: 50615. [167] Bartolome JA, Silvestre FT, Kamimura S, Arteche ACM, Melendez P, Kelbert D, et al. Resynchronisation of ovulation and timed insemination in lactating dairy cows, I. use of the Ovsynch and Heatsynch protocols after non-pregnancy diag- nosis by ultrasonography. Theriogenology 2005;63:161727. [168] Deligiannis C, Valasi I, Rekkas CA, Goulas P, Theodosiadou E, Lainas T, et al. Synchronization of ovulation and xed time intrauterine insemination in ewes. Reprod Domest Anim 2005; 40:610. [169] Pursley JR, Mee MO, Wiltbank MC. Synchronization of ovula- tion in dairy cows using PGF2a and GnRH. Theriogenology 1995;44:91523. [170] Twagiramungu H, Guilbault LA, Dufour JJ. Synchronization of ovarian follicular waves with a gonadotropin-releasing hor- mone agonist to increase the precision of estrus in cattle: a review. J Anim Sci 1995;73:314151. [171] Gong JG, Bramley TA, Gutierrez CG, Peters AR, Webb R. Effects of chronic treatment with gonadotrophin-releasing hormone agonist on peripheral concentrations of FSH and LH, and ovarian function in heifers. J Reprod Fertil 1995; 105:26370. [172] Maclellan LJ, Bergfeld EGM, Earl CR, Fitzpatrick LA, Aspden WJ, Kinder JE, et al. Inuence of the luteinizing hormone- releasing hormone agonist, deslorelin, on patterns of estradiol- 17b and luteinizing hormone secretion, ovarian follicular responses to superstimulation with follicle-stimulating hor- mone, and recovery and in vitro development of oocytes in heifer calves. Biol Reprod 1997;56:87884. [173] Rajamahendran R, Ambrose JD, Schmitt EJ, Thatcher MJ, Thatcher WW. Effects of buserelin injection and deslorelin (GnRH-agonist) implants on plasma progesterone, LH, acces- sory CL formation, follicle and corpus luteum dynamics in Holstein cows. Theriogenology 1998;50:114155. [174] DOcchio MJ, Fordyce G, Whyte TR, Aspden WJ, Trigg TE. Reproductive responses of cattle to GnRH agonists. Anim Reprod Sci 2000;6061:43342. [175] Schneider F, Heleil B, Alm H, Torner H, Becker F, Viergutz T, et al. Endocrine, morphological, and cytological effects of a depot GnRH agonist in bovine. Anim Reprod Sci 2006;92: 928. [176] Adams TE. Using gonadotropin-releasing hormone (GnRH) and GnRH analogs to modulate testis function and enhance the productivity of domestic animals. Anim Reprod Sci 2005; 88:12739. [177] Xue JL, Dial GD, Bartsh S, Kerkeart B, Squires EJ, Marsh WE, et al. Inuence of a gonadotropin-releasing hormone agonist on circulating concentrations of luteinizing hormone and testos- terone and tissue concentrations of compounds associated with boar taint. J Anim Sci 1994;72:12908. [178] Schneider F, Falkenberg H, Kuhn G, Nurnberg K, Rehfeldt C, Kanitz W. Effects of treating young boars with a GnRH depot formulation on endocrine functions, testis size, boar taint, carcass composition and muscular structure. Anim Reprod Sci 1998;50:6980. [179] Magdwick S, Evans ACO, Beard AP. Treating heifers with GnRH from 4 to 8 weeks of age advanced growth and the age at puberty. Theriogenology 2005;63:232333. [180] Esbenshade KL, Britt JH. Active immunization of gilts against gonadotropin-releasing hormone: effects on secretion of gona- dotropins. reproductive function, and responses to agonists of gonadotropin-releasing hormone. Biol Reprod 1985;33: 56977. [181] Prendiville DJ, Enright WJ, Crowe MA, Finnerty M, Roche JF. Normal or induced secretory patterns of luteinising hormone and follicle-stimulating hormone in anoestrous gonadotrophin- releasing hormone-immunised and cyclic control heifers. Anim Reprod Sci 1996;45:17790. [182] Stevens JD, Sosa JM, DeAvila DM, Oatley JM, Bertrand KP, Gaskins CT, et al. Luteinizing-hormone-releasing hormone fusion protein vaccines block estrous cycle activity in beef heifers. J Anim Sci 2005;83:1529. [183] Brown BW, Mattner PE, Carroll PA, Hoskinson RM, Rigby RDG. Immunization of sheep against GnRH early in life: effects on reproductive function and hormones in ewes. J Reprod Fertil 1995;103:1315. [184] Mariana JC, Monniaux D, Craty A, Pisselet C, Fontaine J, Solari A. Immunization of sheep against GnRH early in life: effects on gonadotropins, follicular growth and responsiveness of granulosa cells to FSHand IGF-I in two breeds of sheep with different prolicacy (Romanov and Ile-de-France). Domest Anim Endocrinol 1998;15:195207. [185] Tast A, Love RJ, Clarke W, Evans G. Effects of active and passive gonadotropin-releasing hormone immunization on recognition and establishment of pregnancy in pigs. Reprod Fertil Dev 2000;12:27782. [186] Driancourt MA, Locatelli A, Prunier A. Effects of gonadotro- phin deprivation on follicular growth in gilts. Reprod Nutr Dev 1995;35:66373. [187] Dobson H, Campbell BK, Scaramuzzi RJ. Use of a GnRH antagonist in conjunction with low amplitude, high frequency LH pulses to induce follicular growth without an LH surge and ovulation. Anim Reprod Sci 1997;46:21322. [188] Fike KE, Bergfeld EG, Cupp AS, Kojima FN, Mariscal V, Sanchez T, et al. Gonadotropin secretion and ovarian follicles during oestrous cycles in heifers treated with luteinizing hor- mone releasing hormone antagonist. Anim Reprod Sci 1997; 49:83100. [189] Patterson-Day DJ, Geisert RD, Hill CM, Minton JE, McCann JP, Morgan GL. GnRH antagonist inhibition of luteinizing hormone secretion and ovulation in the pig. Anim Reprod Sci 1997;49:20714. [190] Oussaid B, Mariana JC, Poulin N, Fontaine J, Lonergan P, Beckers JF, et al. Reduction of the developmental competence of sheep oocytes by inhibition of LHpulses during the follicular phase with a GnRH antagonist. J Reprod Fertil 1999;117:717. [191] Brussow KP, Schneider F, Nurnberg G. Alteration of gona- dotrophin and steroid hormone release, and ovarian function by a GnRH antagonist in gilts. Anim Reprod Sci 2001;66: 11728. [192] Gautron JP, Gras C, Enjalbert A. Molecular polymorphism of native gonadotropin-releasing hormone (GnRH) is restricted to F. Schneider et al. / Theriogenology 66 (2006) 691709 708 mammalian GnRH and [hydroxyproline] GnRH in the devel- oping rat brain. Neuroendocrinology 2005;81:6986. [193] Kauffold J, Schneider F, Zaremba W, Brussow KP. Lamprey GnRH-III (l-GnRH-III) selectively elicits FSH response after administration to barrows. Reprod Domest Anim 2005;40: 4759. [194] Porter MB, Cleaver BD, Peltier M, Robinson G, Thatcher WW, Sharp DC. Comparative study between pony mares and ewes evaluating gonadotrophic response to administration of gonadotrophin-releasing hormone. J Reprod Fertil 1997;110: 21929. [195] Khosravi S, Leung PC. Differential regulation of gonadotropin- releasing hormone (GnRH)I and GnRHII messenger ribonu- cleic acid by gonadal steroids in human granulosa luteal cells. J Clin Endocrinol Metab 2003;88:66372. [196] Siler-Khodr TM, Yu FQ, Wei P, Tao SX, Liu YX. Contraceptive action of a gonadotropin-releasing hormone II analog in the rhesus monkey. J Clin Endocrinol Metab 2004;89:451320. F. Schneider et al. / Theriogenology 66 (2006) 691709 709